Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
2000 1
2001 4
2002 5
2003 7
2004 6
2005 12
2006 1
2007 5
2008 4
2009 7
2010 11
2011 13
2012 12
2013 9
2014 7
2015 9
2016 12
2017 7
2018 8
2019 1
2020 6
2021 11
2022 8
2023 4
2024 6
2025 11

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

162 results

Results by year

Filters applied: . Clear all
Page 1
Empagliflozin in Heart Failure with a Preserved Ejection Fraction.
Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, Brunner-La Rocca HP, Choi DJ, Chopra V, Chuquiure-Valenzuela E, Giannetti N, Gomez-Mesa JE, Janssens S, Januzzi JL, Gonzalez-Juanatey JR, Merkely B, Nicholls SJ, Perrone SV, Piña IL, Ponikowski P, Senni M, Sim D, Spinar J, Squire I, Taddei S, Tsutsui H, Verma S, Vinereanu D, Zhang J, Carson P, Lam CSP, Marx N, Zeller C, Sattar N, Jamal W, Schnaidt S, Schnee JM, Brueckmann M, Pocock SJ, Zannad F, Packer M; EMPEROR-Preserved Trial Investigators. Anker SD, et al. N Engl J Med. 2021 Oct 14;385(16):1451-1461. doi: 10.1056/NEJMoa2107038. Epub 2021 Aug 27. N Engl J Med. 2021. PMID: 34449189 Clinical Trial.
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M, Jamal W, Kimura K, Schnee J, Zeller C, Cotton D, Bocchi E, Böhm M, Choi DJ, Chopra V, Chuquiure E, Giannetti N, Janssens S, Zhang J, Gonzalez Juanatey JR, Kaul S, Brunner-La Rocca HP, Merkely B, Nicholls SJ, Perrone S, Pina I, Ponikowski P, Sattar N, Senni M, Seronde MF, Spinar J, Squire I, Taddei S, Wanner C, Zannad F; EMPEROR-Reduced Trial Investigators. Packer M, et al. N Engl J Med. 2020 Oct 8;383(15):1413-1424. doi: 10.1056/NEJMoa2022190. Epub 2020 Aug 28. N Engl J Med. 2020. PMID: 32865377 Free article. Clinical Trial.
Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation.
Okumura K, Akao M, Yoshida T, Kawata M, Okazaki O, Akashi S, Eshima K, Tanizawa K, Fukuzawa M, Hayashi T, Akishita M, Lip GYH, Yamashita T; ELDERCARE-AF Committees and Investigators. Okumura K, et al. N Engl J Med. 2020 Oct 29;383(18):1735-1745. doi: 10.1056/NEJMoa2012883. Epub 2020 Aug 30. N Engl J Med. 2020. PMID: 32865374 Clinical Trial.
Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy.
Desai MY, Owens AT, Abraham T, Olivotto I, Garcia-Pavia P, Lopes RD, Elliott P, Fernandes F, Verheyen N, Maier L, Meder B, Azevedo O, Kitaoka H, Wolski K, Wang Q, Jaber W, Mitchell L, Myers J, Rano T, Gong Z, Zhong Y, Carter-Bonanza S, Florea V, Aronson R, Nissen SE; ODYSSEY-HCM Investigators. Desai MY, et al. N Engl J Med. 2025 Sep 11;393(10):961-972. doi: 10.1056/NEJMoa2505927. Epub 2025 Aug 30. N Engl J Med. 2025. PMID: 40888717 Clinical Trial.
Phase 3 Open-Label Study Evaluating the Efficacy and Safety of Mavacamten in Japanese Adults With Obstructive Hypertrophic Cardiomyopathy　- The HORIZON-HCM Study.
Kitaoka H, Ieda M, Ebato M, Kozuma K, Takayama M, Tanno K, Komiyama N, Sakata Y, Maekawa Y, Minami Y, Ogimoto A, Takaya T, Yasuda S, Amiya E, Furukawa Y, Watanabe T, Hiraya D, Miyagoshi H, Kinoshita G, Reedy A, Hegde SM, Florea V, Izumi C. Kitaoka H, et al. Among authors: ogimoto a. Circ J. 2024 Dec 25;89(1):130-138. doi: 10.1253/circj.CJ-24-0501. Epub 2024 Nov 7. Circ J. 2024. PMID: 39505542 Free article. Clinical Trial.
Echocardiographic Changes With Mavacamten in Nonobstructive Hypertrophic Cardiomyopathy: Exploratory Insights From the ODYSSEY-HCM Trial.
Desai MY, Okushi Y, Jadam S, Olivotto I, Owens A, Nissen SE, Popovic ZB, Garcia-Pavia P, Lopes RD, Elliott PM, Fernandes F, Geske JB, Maier L, Wolski K, Wang Q, Jaber W, Gong Z, Florea V, Fronheiser M, Leva A, Aronson R, Abraham T; ODYSSEY-HCM Investigators. Desai MY, et al. J Am Coll Cardiol. 2025 Dec 16;86(24):2434-2449. doi: 10.1016/j.jacc.2025.08.019. Epub 2025 Aug 27. J Am Coll Cardiol. 2025. PMID: 40864019 Clinical Trial.
Contemporary clinical characteristics and management patterns in hypertrophic cardiomyopathy: insights from baseline enrolment data in a nationwide prospective Japanese registry.
Kubo T, Sugiura K, Tokita Y, Takano H, Takamisawa I, Takayama M, Doi YL, Minami Y, Shirotani S, Ebato M, Tsujiuchi M, Nabeta T, Inomata T, Kato T, Okamoto R, Dohi K, Takei Y, Chikamori T, Watanabe E, Furugen A, Doi H, Akita K, Maekawa Y, Ogimoto A, Tada N, Yokota T, Ikeda S, Yamaguchi O, Izumiya Y, Shibata A, Takashio S, Tsujita K, Maejima Y, Fujino N, Nomura A, Akasaki Y, Higuchi K, Fujita S, Hoshiga M, Shiraishi Y, Ieda M, Miyamoto Y, Kitaoka H. Kubo T, et al. Among authors: ogimoto a. Heart. 2025 Aug 26;111(18):885-892. doi: 10.1136/heartjnl-2024-324811. Heart. 2025. PMID: 40037766 Free PMC article.
Fatal Disease Causing Secondary Pericarditis.
Tasaka T, Inaba S, Kono T, Ohshima K, Ogimoto A. Tasaka T, et al. Among authors: ogimoto a. Circ J. 2023 Feb 24;87(3):466. doi: 10.1253/circj.CJ-22-0602. Epub 2022 Dec 10. Circ J. 2023. PMID: 36504083 Free article. No abstract available.
Lung Cancer in the Left Atrium.
Miyazaki S, Inaba S, Inoue K, Yamaguchi O, Matsukage S, Ogimoto A. Miyazaki S, et al. Among authors: ogimoto a. Circ J. 2022 Apr 25;86(5):878. doi: 10.1253/circj.CJ-21-0946. Epub 2021 Dec 17. Circ J. 2022. PMID: 34924464 Free article. No abstract available.
162 results